Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ejh.13593 http://scihub22266oqcxt.onion/10.1111/ejh.13593 33523540!ä!33523540 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Haematol 2021 ; 106 (5): 654-661 Nephropedia Template TP {{tp|p=33523540|t=2021. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series |pdf=|usr=}}{{33523540}} gab.com Text Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series JO: Eur J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=33523540 #FOAvip INTRODUCTION: Hemophagocytic lymphohistiocytosis (HLH) is a cytokine storm syndrome associated with mortality rates of up to 88%. Standard therapy with high-dose glucocorticoids and etoposide used in adults is extrapolated from pediatric trials, with significant toxicity in older patients and those with poor performance status. The JAK1/2 inhibitor ruxolitinib has recently gained attention as a treatment option for HLH due to its broad cytokine-modulating abilities and safety profile. Herein we report our center's experience using ruxolitinib in the treatment of adult-onset secondary HLH. CASE SERIES: We report four patients with profound secondary HLH provoked by diverse triggers, including invasive pulmonary aspergillosis on background systemic lupus erythematosus, disseminated tuberculosis, and T-cell lymphoma treated with ruxolitinib as monotherapy or combination therapy in upfront and salvage settings. RESULTS: All four patients had rapid, sustained improvement in clinical status, inflammatory markers, and hematological cell counts followed by durable remission. Three patients developed manageable infectious complications postruxolitinib. CONCLUSIONS: This series demonstrates the effective use of JAK inhibition with ruxolitinib to control pathological immune activation in critically ill patients with secondary HLH and otherwise limited therapeutic options. JAK inhibition is also an area of urgent investigation for the treatment of cytokine storm associated with COVID-19. Twit Text FOAVip Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series ????Eur J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=33523540 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33523540 #FOAvip English Wikipedia <ref>{{Cite pmid|33523540}}</ref> Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series #MMPMID33523540 Hansen S; Alduaij W; Biggs CM; Belga S; Luecke K; Merkeley H; Chen LYC Eur J Haematol 2021[May]; 106 (5): 654-661 PMID33523540show ga INTRODUCTION: Hemophagocytic lymphohistiocytosis (HLH) is a cytokine storm syndrome associated with mortality rates of up to 88%. Standard therapy with high-dose glucocorticoids and etoposide used in adults is extrapolated from pediatric trials, with significant toxicity in older patients and those with poor performance status. The JAK1/2 inhibitor ruxolitinib has recently gained attention as a treatment option for HLH due to its broad cytokine-modulating abilities and safety profile. Herein we report our center's experience using ruxolitinib in the treatment of adult-onset secondary HLH. CASE SERIES: We report four patients with profound secondary HLH provoked by diverse triggers, including invasive pulmonary aspergillosis on background systemic lupus erythematosus, disseminated tuberculosis, and T-cell lymphoma treated with ruxolitinib as monotherapy or combination therapy in upfront and salvage settings. RESULTS: All four patients had rapid, sustained improvement in clinical status, inflammatory markers, and hematological cell counts followed by durable remission. Three patients developed manageable infectious complications postruxolitinib. CONCLUSIONS: This series demonstrates the effective use of JAK inhibition with ruxolitinib to control pathological immune activation in critically ill patients with secondary HLH and otherwise limited therapeutic options. JAK inhibition is also an area of urgent investigation for the treatment of cytokine storm associated with COVID-19. |Adult[MESH] |COVID-19/complications[MESH] |Combined Modality Therapy[MESH] |Cytokine Release Syndrome/drug therapy/etiology[MESH] |Cytokines/blood[MESH] |Female[MESH] |Humans[MESH] |Invasive Pulmonary Aspergillosis/complications[MESH] |Janus Kinases/*antagonists & inhibitors[MESH] |Lupus Erythematosus, Systemic/complications[MESH] |Lymphohistiocytosis, Hemophagocytic/*drug therapy/etiology[MESH] |Lymphoma, T-Cell/complications[MESH] |Male[MESH] |Middle Aged[MESH] |Nitriles[MESH] |Protein Kinase Inhibitors/*therapeutic use[MESH] |Pyrazoles/*therapeutic use[MESH] |Pyrimidines[MESH] |SARS-CoV-2[MESH] |Salvage Therapy[MESH] |Tuberculosis/complications[MESH]Ruxolitinib as adjunctive therapy for secondary hemophagocytic lympho(epmc).pdf DeepDyve Pubget Overpricing